Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826612 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
A Phase 1 study of Huntington Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 5
- Study locations
NCT06826612: Recruiting Phase 1 study of Huntington Disease, sponsored by Hoffmann-La Roche.
NCT06826612 is a Phase 1 study of Huntington Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 53 participants, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06826612, a Phase 1 study of Huntington Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Conditions Studied
Interventions
- GENETIC SPK-10001
- OTHER Placebo Surgery Control
Study Locations (5)
Ohio
- University of Cincinnati/Cincinnati Children's Hospital - Cincinnati
- Ohio State University - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburg - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2035-01-12 |
| Phase | Phase 1 |
What NCT06826612 shows while recruiting
NCT06826612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 634-participant average among 35 other Huntington Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which SPK-10001 is the first listed.
NCT06826612 lists 5 locations in 3 states (Ohio, Pennsylvania, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06826612 about?
NCT06826612 is a clinical study titled "A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease". The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
What is the current status of trial NCT06826612?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2025-02-21. Estimated completion is 2035-01-12.
What conditions does trial NCT06826612 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06826612?
The interventions under investigation include: SPK-10001 (GENETIC), Placebo Surgery Control (OTHER).
Who is sponsoring clinical trial NCT06826612?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826612 being conducted?
This trial has 5 study locations across Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06826612's enrollment target sits among peer trials
53 24th of 35 higher than 12 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
COMPLETED · Phase 1
-
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
COMPLETED · Phase 1
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI